Parkman Healthcare Partners LLC Bio Line Rx Ltd. Transaction History

Parkman Healthcare Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.88 - $1.91 $2,990 - $6,490	3,398 Added 1.19%	288,852 $267,000
Q2 2022 Aug 12, 2022	BUY	$1.06 - $1.82 $15,676 - $26,915	14,789 Added 5.46%	285,454 $365,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.18 $230,595 - $344,313	-157,942 Reduced 36.85%	270,665 $463,000
Q4 2021 Feb 11, 2022	BUY	$1.98 - $3.06 $34,743 - $53,693	17,547 Added 4.27%	428,607 $874,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $3.35 $855,875 - $1.08 Million	-322,972 Reduced 44.0%	411,060 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$2.63 - $4.88 $799,317 - $1.48 Million	303,923 Added 70.66%	734,032 $2.06 Million
Q1 2021 May 14, 2021	BUY	$2.38 - $4.0 $5,155 - $8,664	2,166 Added 0.51%	430,109 $1.2 Million
Q4 2020 Feb 12, 2021	BUY	$1.47 - $3.62 $629,076 - $1.55 Million	427,943 New	427,943 $1.08 Million

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.